Amplexor uses functional, analytical and tracking cookies to improve the performance and security of its website, and, where permitted, to analyse website use for business and website optimization purposes. You can directly agree to all these cookies or change the cookie settings. if you do not want us to share this information. For further information about the cookies we use, please see our Privacy Policy.
Amplexor in European Biopharmaceutical Review
by Romuald Braun, VP of Strategy at Amplexor
With regulatory compliance growing, we should expect to see data management transformation rising. However, this is not the case. Instead, we see companies throwing good money after bad money as they opt to invest in digitizing a process or updating an existing IT system. While, encouragingly, in 2019 organisations now appear to recognize the need for a more holistic approach, Life Sciences companies will need to focus attention on developing a vision for delivering this and mapping it to a hard strategy. Read the full article and learn more about why it's important for Life Sciences companies to move from approaching each project in isolation, to viewing them as part of a bigger vision.
This article is taken from European Biopharmaceutical Review January 2019, pages 86-87. © Samedan Ltd.